# US 2025/0144229 A1 · Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144229 A1
- Document ID: US20250144229A1
- Status: Published application
- Kind: A1
- Application number: 18/837,951
- Filed: 2023-02-15
- Published: 2025-05-08
- Earliest claimed: 2022-02-16
- Assignees: Medlink Therapeutics (Suzhou) Co., Ltd.
- Applicants: Medlink Therapeutics (Suzhou) Co., Ltd.
- Inventors: Tongtong XUE; Liang XIAO; Shuai SONG; Xinzhen SHI; Jundong LI; Jiaqiang CAI
- Web page: https://patentgrep.com/patent/US20250144229A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A conjugate of antibody-eribulin or a derivative thereof, an intermediate thereof, a preparation method therefor, a pharmaceutical composition thereof and use thereof. The conjugate of the antibody-eribulin or the derivative thereof provided herein as shown in general formula I is shown below. The conjugate of general formula I has high anti-tumor activity and high stability in circulation, and has excellent tumor tissue targeting property and therapeutic indexes.

## Claims

### Claim 1

A conjugate of antibody-eribulin or a derivative thereof of formula I,
or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,
wherein
Tb is an antibody or an antigen-binding fragment thereof that binds to a target, or a targeting moiety;
q is a drug-to-Tb coupling ratio;
R1 and R2 are each independently selected from hydrogen, deuterium, and C1-6 alkyl; or, R1 and R2 together with the nitrogen atom and the oxygen atom to which they are attached form a 5- to 6-membered heterocyclic ring; the 5- to 6-membered heterocyclic ring is optionally substituted by one or more substituents of C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, and C3-6 heterocyclyl;
L1 is selected from
position 1 is attached to Tb via an S atom and position 2 is attached to L2;
Rc is selected from hydrogen and C1-6 alkyl;
L2 is selected from
position 1 is attached to L1 and position 2 is attached to L3;
p is selected from any integer between 0 and 10;
Y is selected from —CH2— and —OCH2CH2—;
Z is selected from —CR3R4— and —NR5—;
R3 and R4 are each independently selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, and C3-6 heterocyclyl; or, R3 and R4 together with the carbon atom to which they are attached form a 3- to 6-membered carbocyclic ring or a 3- to 6-membered heterocyclic ring;
R5 is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, and C3-6 heterocyclyl;
L3 is selected from a chemical bond,
an amino acid residue, or a short peptide consisting of 2 to 10 amino acid residues; the amino acid residue is selected from a natural amino acid residue, an unnatural amino acid residue, or an amino acid residue represented by AA1 or a stereoisomer thereof;
the amino acid residue represented by AA1 has a structure as follows,
wherein
Ra and Rb are each independently selected from hydrogen and
and Ra and Rb are not both hydrogen;
or, Ra and Rb together with the carbon atom to which they are both attached form a 4- to 10-membered heterocyclic ring; the 4- to 10-membered heterocyclic ring is optionally substituted by one or more R0;
r and r1 are each independently selected from any integer between 0 and 20;
Rm1 and Rn1 are each independently selected from hydrogen, C1-6 alkyl, and C3-6 cycloalkyl;
or, Rm1 and Rn1 together with the nitrogen atom to which they are both attached form a 4- to 10-membered heterocyclic ring; the 4- to 10-membered heterocyclic ring is optionally substituted by one or more R0′;
R0 and R0′ are each independently selected from C1-6 alkyl, C3-6 cycloalkyl, —NRm2Rn2, and optionally C1-6 alkyl-substituted 4- to 10-membered heterocyclyl;
Rm2 and Rn2 are each independently selected from hydrogen and C1-6 alkyl;
L4 is absent or present; when L4 is present, L4 is selected from
position 1 is attached to L3 and position 2 is attached to the nitrogen atom of eribulin;
and, when L1 is
position 1 is attached to Tb via an S atom, and position 2 is attached to L2:
L3 is not a chemical bond, Val-Cit, Val-Lys, Gly-Gly-Phe-Gly, or Ala-Ala-Asn; or,
L4 is present and is not

### Claim 2 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein one or more of the following conditions are satisfied:
(1) Tb is an antibody or an antigen-binding fragment thereof, which satisfies one or more of the following conditions:
(i) the antibody or the antigen-binding fragment thereof comprise Fab, Fab′, F(ab′)2, Fd, Fv, dAb, complementarity determining region fragment, non-human antibody, humanized antibody, chimeric antibody, fully human antibody, probody, monoclonal antibody, bispecific antibody, or multi-specific antibody;
(ii) Tb is a monoclonal antibody or an antigen-binding fragment;
(iii) Tb is an antibody or an antigen-binding fragment thereof which has endocytic activity;
(iv) Tb is an antibody or an antigen-binding fragment thereof which has the activity of binding to a free antigen in tumor tissues and/or a tumor cell surface antigen;
(v) Tb is selected from an antibody or an antigen-binding fragment thereof that binds to the following targets: growth factor, integrin α5β6, integrin α4β7, 0772P, 5T4, ACTA2, ADGRE1, AGS-16, AIF1, AKR1C1, AKR1C2, ANGPTL4, ApoE, ASLG659, BAFF-R, BMPR1B, BNIP3, Brevican, C1QA, C1QB, CA6, pCAD, P-cadherin, CADM1, CCL5, CCR5, CD1 lb, CD1 lc, CD19, CD20, CD21, CD22, CD30, CD33, CD37, CD40, CD45 (PTPRC), CD49D (ITGA4), CD56, CD66e, CD70, CD72, CD74, CD79a, CD80, CD138, CD223, CDCP1, CDH11, Claudin18.2, COL6A3, COL7A1, CRIPTO, CSF1R, CTGF, CTSD, CTSS, CXCL10, CXCL11, CXCR5, DDIT4, DLL3, DLL4, DR5, E16, EFNA4, B7H3, EGFR, EGFRvIII, EGLN, EGLN3, EMR2, Endothelin receptor, ENPP3, EpCAM, EphB2R, ETBR, FGF2, FGFR2, FcRH1, FcRH2, GEDA, GPNMB, GZMB, Her2, Her3, HLA-DOB, HMOX1, IFNG, IFI6, IGF-1R, IGFBP3, IL10RA1, IL20Rα, IL-6, IRTA2, KISS1R, KRT33A, LOX, LRRC15, LUM, LY6E, LY64, LY86, LYPD3, MCPT8, MDP, Mesothelin, c-Met, MFI2, MMP10, MMP14, MMP16, MPF, MSG783, MS4A7, MUC 1, MUC16, NaPi2b, NaPi3b, NCA, Nectin 4, NOG, P2X5, PD-L1, PDK1, PDGFRA, PFKFB3, PGF, PGK1, PIK3AP1, PIK3CD, PLOD2, PSCA, PSCAh1g, PSMA, RNF43, ROR1, Sema5b, SERPINE1, SLC39A6, SLITRK6, SLTRK6, STAT1, STC2, STEAP1, STEAP2, TCF4, TENB2, TGF, TGFBR1, TGFB2, Tissue factor, TNFRSF21, TNFSF9, Trop-2, TrpM4, Tyro7, UPK1B, VEGFA, and WNT5A;
(vi) Tb is an anti-B7H3 antibody or an antigen-binding fragment thereof, an anti-Trop-2 antibody or an antigen-binding fragment thereof, an anti-Her2 antibody or an antigen-binding fragment thereof, an anti-Her3 antibody or an antigen-binding fragment thereof, or an anti-EGFR antibody or an antigen-binding fragment thereof,
(2) the q is selected from any numerical value between 0.1 and 16.0; preferably, q is selected from any numerical value between 1 and 10; more preferably, q is selected from 1, 2, 3, 4, 5, 6, 7, and 8;
(3) the R1 and R2 are hydrogen; or, R1 and R2 together with the nitrogen atom and the oxygen atom to which they are attached form
and position 1 is attached to L4 or L3;
(4) the L1 is selected from
position 1 is attached to Tb via an S atom and position 2 is attached to L2;
preferably, L1 is selected from
position 1 is attached to Tb via an S atom and position 2 is attached to L2; more preferably, L1 is
position 1 is attached to Tb via an S atom and position 2 is attached to L2;
(5) the R0 is hydrogen;
(6) the p is selected from 0, 1, 2, 3, 4, 5, 6, 7, and 8;
(7) the Z is —CH2—, —C(CH3)2—, or —NH—;
(8) the R3 and R4 are each independently selected from hydrogen and methyl;
(9) the R5 is H or methyl;
(10) the L3 is selected from amino acid residues Val, D-Val, Cit, Phe, Lys, Lys(Ac), Leu, Gly, Ala, Asn, Asp, Arg, and AA1, or a short peptide consisting of 2 to 10 amino acid residues selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Asp, and AA1;
preferably, L3 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, AA1, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), Ala-Ala, Val-AA1, Ala-AA1, Gly-AA1, AA1-Gly, Ala-Ala-Ala, Ala-Ala-Asn, Ala-Ala-Asp, Val-AA1-Gly, Ala-AA1-Gly, Gly-AA1-Gly, Lys-(Ala)2-Asn, Lys-(Ala)2-Asp, Gly-Phe-Gly, (Gly)2-Phe-Gly, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn, Gly-Gly-Phe, Val-Lys-Gly, Val-Lys-(Gly)2, Val-Lys, Lys-Ala-Asn, and (Gly)2-Phe-AA1;
more preferably, L3 is selected from Val-AA1-Gly, Val-AA1, Val-Cit, and (Gly)2-Phe-AA1; particularly preferably, L3 is selected from Val-AA1 and Val-Cit;
(11) one of the Ra and Rb is hydrogen, and the other is
or, Ra and Rb together with the carbon atom to which they are both attached form a 5- to 6-membered heterocyclic ring substituted by R0; preferably, Ra and Rb together with the carbon atom to which they are both attached form
the carbon atom marked with number 1 is the carbon atom to which Ra and Rb are both attached;
(12) the r and r1 are each independently selected from 0, 1, 2, 3, 4, and 5; preferably, r and r1 are each independently selected from 0 and 4; more preferably, r is 0 and r1 is 4;
(13) the Rm1 and Rn1 are each independently selected from C1-6 alkyl; or, Rm1 and Rn1 together with the nitrogen atom to which they are both attached form a 5- to 6-membered heterocyclic ring optionally substituted by R0′;
preferably, Rm1 and Rn1 are each independently selected from methyl, ethyl, n-propyl, and n-butyl; or, Rm1 and Rn1 together with the nitrogen atom to which they are both attached form a piperidine ring or a piperazine ring, and the piperidine ring and the piperazine ring are optionally substituted by R0′;
(14) the R0 and R0′ are each independently selected from C1-6 alkyl, —NRm2Rn2, and optionally C1-6 alkyl-substituted 5- to 6-membered heterocyclyl;
(15) the Rm2 and Rn2 are methyl; and
(16) the L2 is selected from
position 1 is attached to L1 and position 2 is attached to L3.

### Claim 3 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein one or more of the following conditions are satisfied:
(1) L2 is selected from
position 1 is attached to L1 and position 2 is attached to L3; preferably, L2 is
position 1 is attached to L1 and position 2 is attached to L3;
(2) L3 is selected from a chemical bond,
position 1 is attached to L2 and position 2 is attached to L4 or the nitrogen atom of eribulin;
preferably, L3 is selected from
position 1 is attached to L2 and position 2 is attached to L4 or the nitrogen atom of eribulin;
more preferably, L3 is selected from
position 1 is attached to L2 and position 2 is attached to L4 or the nitrogen atom of eribulin;
particularly preferably, L3 is selected from
position 1 is attached to L2 and position 2 is attached to L4 or the nitrogen atom of eribulin;
(3) the amino acid residue represented by AA1 is selected from
preferably, the amino acid residue represented by AA1 is selected from
more preferably, the amino acid residue represented by AA1 is
and
(4) L4 is absent or present; when L4 is present, L4 is selected from
position 1 is attached to L3 and position 2 is attached to the nitrogen atom of eribulin;
preferably, L4 is
position 1 is attached to L3 and position 2 is attached to the nitrogen atom of eribulin.

### Claim 4 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, wherein the linker
is selected from a linker of the following formulas:
wherein position 1 is attached to Tb via an S atom and position 2 is attached to the nitrogen atom of eribulin;
preferably, the linker
is selected from a linker of the following formulas:
wherein position 1 is attached to Tb via an S atom and position 2 is attached to the nitrogen atom of eribulin;
more preferably, the linker
is selected from a linker of the following formulas:
wherein position 1 is attached to Tb via an S atom and position 2 is attached to the nitrogen atom of eribulin.

### Claim 5 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein the linker
is selected from the following:
position 1 is attached to Tb via an S atom and position 2 is attached to the nitrogen atom of eribulin;
preferably, the linker
is selected from the following:
position 1 is attached to Tb via an S atom and position 2 is attached to the nitrogen atom of eribulin;
more preferably, the linker
is selected from the following:
position 1 is attached to Tb via an S atom and position 2 is attached to the nitrogen atom of eribulin.

### Claim 6 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein the conjugate of antibody-eribulin or the derivative thereof is selected from:

### Claim 7 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein Tb is any one of the following schemes:
(i) Tb is an anti-Her2 antibody or an antigen-binding fragment thereof, wherein the anti-Her2 antibody is anbenitamab, coprelotamab, disitamab, gancotamab, margetuximab, pertuzumab, timigutuzumab, zanidatamab, trastuzumab, pertuzumab, or an antigen-binding fragment thereof;
(ii) Tb is an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein the anti-Trop-2 antibody is datopotamab, sacituzumab, or an antigen-binding fragment thereof;
(iii) Tb is an anti-EGFR antibody or an antigen-binding fragment thereof, wherein the anti-EGFR antibody is demupitamab, depatuxizumab, futuximab, imgatuzumab, laprituximab, losatuxizumab, matuzumab, modotuximab, necitumumab, nimotuzumab, panitumumab, pimurutamab, serclutamab, tomuzotuximab, zalutumumab, cetuximab, or an antigen-binding fragment thereof;
(iv) Tb is an anti-B7H3 antibody or an antigen-binding fragment thereof, wherein the anti-B7H3 antibody is enoblituzumab, mirzotamab, omburtamab, antibody 1D1-01, antibody 2E3-02, or an antigen-binding fragment thereof;
(v) Tb is an anti-B7H3 antibody or an antigen-binding fragment thereof, wherein the anti-B7H3 antibody or the antigen-binding fragment thereof comprises a complementarity determining region (CDR) as follows, wherein the CDR is defined by the Kabat numbering system:
HCDR1 with the sequence of SEQ ID NO: 9, HCDR2 with the sequence of SEQ ID NO: 10, and HCDR3 with the sequence of SEQ ID NO: 11; and/or,
LCDR1 with the sequence of SEQ ID NO: 12, LCDR2 with the sequence of SEQ ID NO: 13, and LCDR3 with the sequence of SEQ ID NO: 14;
(vi) Tb is an anti-B7H3 antibody or an antigen-binding fragment thereof, wherein the anti-B7H3 antibody or the antigen-binding fragment thereof comprises a complementarity determining region (CDR) as follows, wherein the CDR is defined by the IMGT numbering system:
HCDR1 with the sequence of SEQ ID NO: 15, HCDR2 with the sequence of SEQ ID NO: 16, and HCDR3 with the sequence of SEQ ID NO: 17; and/or, LCDR1 with the sequence of SEQ ID NO: 18, LCDR2 with the sequence of GAS, and LCDR3 with the sequence of SEQ ID NO: 19;
(vii) Tb is an anti-B7H3 antibody or an antigen-binding fragment thereof, wherein the anti-B7H3 antibody or the antigen-binding fragment thereof comprises: a VH set forth in SEQ ID NO: 1 or 5 and/or a VL set forth in SEQ ID NO: 2 or 6;
the anti-B7H3 antibody or the antigen-binding fragment thereof further comprises:
(a) a heavy chain constant region (CH) of a human immunoglobulin or a variant thereof, and/or
(b) a light chain constant region (CL) of a human immunoglobulin or a variant thereof, (viii) Tb is an anti-B7H3 antibody or an antigen-binding fragment thereof, wherein the anti-B7H3 antibody or the antigen-binding fragment thereof comprises:
a VH set forth in SEQ ID NO: 5 and a CH set forth in SEQ ID NO: 20 or a variant thereof, and/or, a VL set forth in SEQ ID NO: 6 and a CL set forth in SEQ ID NO: 21 or a variant thereof;
preferably, the anti-B7H3 antibody or the antigen-binding fragment thereof comprises:
a heavy chain set forth in SEQ ID NO: 3 and/or a light chain set forth in SEQ ID NO: 4; or
a heavy chain set forth in SEQ ID NO: 7 and/or a light chain set forth in SEQ ID NO: 8.

### Claim 8 (depends on 1)

The conjugate according to claim 1, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein the conjugate is selected from any one of the following:
wherein B7H3-mAb is antibody 2E3-02, and q is selected from any integer between 0.1 and 10.0; preferably, q is selected from 1, 2, 3, 4, 5, 6, 7, and 8;
wherein q is selected from any integer between 0.1 and 10.0; preferably, q is selected from 1, 2, 3, 4, 5, 6, 7, and 8;
wherein B7H3-mAb is antibody 2E3-02, and q is selected from any integer between 0.1 and 10.0; preferably, q is selected from 1, 2, 3, 4, 5, 6, 7, and 8; or
wherein q is selected from any integer between 0.1 and 10.0; preferably, q is selected from 1, 2, 3, 4, 5, 6, 7, and 8.

### Claim 9 (depends on 1)

A drug-linker conjugate of formula II,
or a stereoisomer of the drug-linker conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,
wherein
when L1 is
position 1 is attached to Lg and position 2 is attached to L2;
Lg is a leaving group when reacting with Tb;
when L1 is
Lg-L1 is
Tb, L1, L2, L3, L4, Rc, R1, and R2 are as defined in claim 1.

### Claim 10 (depends on 9)

The drug-linker conjugate according to claim 9, or a stereoisomer of the conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein the Lg is selected from halogen, sulfonyl, a tertiary amine salt group (Me3N+, Et3N+), diazonium, —OMs, MeSO2—, and CF3SO3—; preferably, Lg is selected from F, Cl, and MeSO2—; more preferably, Lg is selected from F and MeSO2—.

### Claim 11 (depends on 9)

The drug-linker conjugate according to claim 9, or a stereoisomer of the drug-linker conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein the drug-linker conjugate is selected from:

### Claim 12 (depends on 9)

A linker of formula III,
Lg-L1-L2-L3-L4-Lg1 III
Lg, L1, L2, L3, and L4 are as defined in claim 9; Lg1 is a leaving group when reacting with eribulin or a derivative thereof; preferably, Lg1 is —OH,
or halogen.

### Claim 13 (depends on 1)

A method for preparing the conjugate of formula I according to claim 1, comprising: performing a coupling reaction between a sulfhydryl group on Tb and a drug-linker conjugate of general formula II
wherein Lg is a leaving group when reacting with Tb, and when L1 is
Lg-L1 is

### Claim 14 (depends on 13)

The method according to claim 13, wherein the method comprises the step of performing a coupling reaction between a sulfhydryl group on Tb and the drug-linker conjugate of general formula II
in a suitable solvent and under suitable conditions to form a C—S bond;
the molar ratio of the sulfhydryl group on Tb to the drug-linker conjugate is 1:(1-20), such as 1:(2-20), 1:(4-20), 1:(6-20), 1:(8-20), 1:(10-20), 1:(12-20), 1:(14-20), 1:(16-20), or 1:(18-20);
the coupling reaction is preferably carried out in water and/or an organic solvent; the organic solvent is preferably one or more of N,N-dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, a nitrile solvent (e.g., acetonitrile), and an alcohol solvent (e.g., methanol, ethanol);
the post-treatment operation of the method is a conventional post-treatment method for coupling reactions in the art, preferably purifying the coupling product by chromatography; the chromatography is typically one or more of ion exchange chromatography, hydrophobic chromatography, reversed-phase chromatography, or affinity chromatography.

### Claim 15 (depends on 1)

A conjugate population of antibody-eribulin or a derivative thereof, comprising the conjugate of antibody-eribulin or the derivative thereof according to claim 1, a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, in the conjugate population of antibody-eribulin or the derivative thereof, the conjugate of antibody-eribulin or the derivative thereof has two or more q values;
optionally, the drug-to-antibody ratio (DAR) in the conjugate population of antibody-eribulin or the derivative thereof is selected from an integer or decimal between 1 and 10;
preferably, the drug-to-antibody ratio (DAR) in the conjugate population of antibody-eribulin or the derivative thereof is selected from an integer or decimal between 1 and 8;
more preferably, the drug-to-antibody ratio (DAR) in the conjugate population of antibody-eribulin or the derivative thereof is selected from an integer or decimal between 2 and 8;
further more preferably, the drug-to-antibody ratio (DAR) in the conjugate population of antibody-eribulin or the derivative thereof is selected from 2, 2.5, 3, 3.5, 4, 4.2, 4.5, 5, 5.5, 6, 6.5, 7, 7.2, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.7, 8.9, and 9.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the conjugate of antibody-eribulin or the derivative thereof according to claim 1, a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and optionally one or more pharmaceutically acceptable adjuvants.

### Claim 17 (depends on 1)

A method for treating and/or preventing a disease associated with abnormal cell activity in a subject in need thereof, comprising: administering an effective amount of the conjugate of antibody-eribulin or the derivative thereof according to a claim 1, a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof to the subject;
optionally, the disease associated with abnormal cell activity is a hematological and/or solid tumor, for example selected from esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial cancer, solid tumor, non-Hodgkin lymphoma, central nervous system tumor (e.g., neuroglioma, glioblastoma multiforme, glioma, or sarcoma), prostate cancer, or thyroid cancer.

### Claim 18 (depends on 15)

A pharmaceutical composition comprising the conjugate population of antibody-eribulin or the derivative thereof according to claim 15, and optionally one or more pharmaceutically acceptable adjuvants.

### Claim 19 (depends on 9)

A method for treating and/or preventing a disease associated with abnormal cell activity in a subject in need thereof, comprising: administering an effective amount of the drug-linker conjugate of formula II according to claim 9, a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof to the subject;
optionally, the disease associated with abnormal cell activity is a hematological and/or solid tumor, for example selected from esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial cancer, solid tumor, non-Hodgkin lymphoma, central nervous system tumor (e.g., neuroglioma, glioblastoma multiforme, glioma, or sarcoma), prostate cancer, or thyroid cancer.

### Claim 20 (depends on 15)

A method for treating and/or preventing a disease associated with abnormal cell activity in a subject in need thereof, comprising: administering an effective amount of the conjugate population of antibody-eribulin or the derivative thereof according to claim 15 to the subject;
optionally, the disease associated with abnormal cell activity is a hematological and/or solid tumor, for example selected from esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial cancer, solid tumor, non-Hodgkin lymphoma, central nervous system tumor (e.g., neuroglioma, glioblastoma multiforme, glioma, or sarcoma), prostate cancer, or thyroid cancer.
